Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

References

• Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–8.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• USFDA. FDA Background Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting October 24–25, 2018. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM623913.pdf. Accessed 27 July 2019.
   Google Scholar
• Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581–2586.
   PubMed Web of Science ®Google Scholar
• Finkelstein JB. Drug safety system needs overhaul, experts say. J Natl Cancer Inst. 2006;98:379–381.
   PubMedGoogle Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–2135.
   PubMed Web of Science ®Google Scholar
• US FDA. Guidance for Industry. Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. https://www.fda.gov/media/71297/download. Accessed 27 July 2019.
   Google Scholar
• Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from Here? Reflections from a diabetes care Editors’ expert forum. Diabetes Care.2018;41:14–31.
   PubMed Web of Science ®Google Scholar
• Schnell O, Standl E, Catrinoiu D, et al. Report from the 3rd cardiovascular outcome trial (CVOT) summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD study group. Cardiovasc Diabetol.2018;17:30.
   PubMed Web of Science ®Google Scholar
• Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet.2014;383:2008–2017.
   PubMed Web of Science ®Google Scholar
• Venker BT. Hemoglobin A1c as a surrogate for clinical outcomes in diabetes studies. JAMA.2017;318:200.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gutierrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes.2016;9:504–512.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Krumholz HM. Hemoglobin A1c as a surrogate for clinical outcomes in diabetes studies-reply. JAMA.2017;318:200–201.
   PubMed Web of Science ®Google Scholar
• CenterWatch. FDA Approved Drugs. https://www.centerwatch.com/drug-information/fda-approvals/. Accessed 27 July 2019.
   Google Scholar
• United States National Libracy of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed 27 July 2019.
   Google Scholar
• US Department of Health and Human Services. Clinical Trials Registration and Results Information Submission. https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission. Accessed 27 July 2019.
   Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med.2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet.2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial. JAMA.2019;321:69–79.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med.2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med.2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet.2018;392:1519–1529.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med.2017;377:1228–1239.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med.2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med.2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med.2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med.2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med.2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med.2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med.2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Bossuyt PM, Lee KL. Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? Am Heart J.2000;139:745–751.
   PubMed Web of Science ®Google Scholar
• Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne).2018;9:672
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia.2017;60:215–225.
   PubMed Web of Science ®Google Scholar
• Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ.2007;334:786.
   PubMed Web of Science ®Google Scholar
• Heller SR, Bergenstal RM, White WB, et al. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. Diabetes Obes Metab.2017;19:664–671.
   PubMed Web of Science ®Google Scholar
• Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med.2008;121:748–757.
   PubMed Web of Science ®Google Scholar
• US FDA. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm. Accessed 27 July 2019.
   Google Scholar
• US FDA. Supplement approval: NDA 201280/S-016, NDA 201281/S-019, NDA 208026/S-005, NDA 206073/S-013. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/201280Orig1s016,201281Orig1s019,208026Orig1s005,206073Orig1s013ltr.pdf. Accessed 27 July 2019.
   Google Scholar
• US FDA. Supplement approval: NDA 021995/S-040, NDA 022044/S-042, NDA 202270/S-017. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021995Orig1s040,022044Orig1s042,202270Orig1s017ltr.pdf. Accessed 27 July 2019.
   Google Scholar
• Verma S, Goldenberg RM, Bhatt DL, et al. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open.2017;5:E152–E177.
   PubMedGoogle Scholar
• Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation.2004;109:962–965.
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail.2006;12:694–699.
   PubMed Web of Science ®Google Scholar
• Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail.2017;19:69–77.
   PubMed Web of Science ®Google Scholar
• Margulies KB, Hernandez AF, Redfield MM, et al. Effects of Liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA.2016;316:500–508.
   PubMed Web of Science ®Google Scholar
• Ueda P, Svanstrom H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ.2018;363:k4365.
   PubMed Web of Science ®Google Scholar
• Cohen RM. A1C: does one size fit all? Diabetes Care.2007;30:2756–2758.
   PubMed Web of Science ®Google Scholar
• Malka R, Nathan DM, Higgins JM. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. Sci Transl Med.2016;8:359ra130.
   PubMed Web of Science ®Google Scholar